

ALASKA MEDICAID
Prior Authorization Criteria

RELISTOR® (methylnaltrexone bromide)

Available 8mg/0.4ml syringe, 12mg/0.6ml kit, 12mg/0.6ml syringe, 12mg/0.6ml vial, 150mg tablet

FDA INDICATIONS AND USAGE¹

RELISTOR is an opioid antagonist that comes as a tablet and an injection. The tablet is indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain while the injection is indicated for the treatment of OIC in adults with chronic non-cancer pain and OIC in adults with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.

APPROVAL CRITERIA^{1,2}

1. Patient is 18 year of age or older; **AND**
2. Diagnosis of Opioid-induced constipation (OIC) in adults with chronic non-cancer pain **OR** OIC in adults with advanced illness who are receiving palliative care; **AND**
3. Recipient has been taking opioids for a period longer than 4 weeks; **AND**
4. Recipient does not have or suspected mechanical gastrointestinal obstruction; **AND**
5. Submit dates of trial or inadequate response from at least 2 laxative therapies.

DENIAL CRITERIA^{1,2}

1. Patient is less than 18 years of age; **OR**
2. Recipient does not have a diagnosis of Opioid-induced constipation (OIC) in adults with chronic non-cancer pain **OR** OIC in adults with advanced illness who are receiving palliative care; **AND**
3. Recipient has not taken opioids for a period longer than 4 weeks; **AND**
4. Recipient is at risk or has a suspected mechanical gastrointestinal obstruction; **AND**
5. Dates of trial or inadequate response from at least 2 laxative therapies has not been submitted.

CAUTIONS¹

- There is a potential for gastrointestinal perforation.
- May cause severe or persistent diarrhea.
- Patients should be monitored for symptoms of opioid withdrawal.

DURATION OF APPROVAL

- Approval: up to a maximum of 4 months

QUANTITY LIMITS

- 30 day supply at FDA approved dosage.

ALASKA MEDICAID
Prior Authorization Criteria

REFERENCES/FOOTNOTES:

1. Relistor® [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals, November 2018.
2. American Gastroenterological Association Technical Review on Constipation. Bharucha, Adil E.Pemberton, John H.Locke, G. Richard et al. Gastroenterology , Volume 144 , Issue 1 , 218 - 238